EPANOVA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EPANOVA (EPANOVA).
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
| Metabolism | Epanova (omega-3-carboxylic acids) is hydrolyzed by pancreatic lipase; free fatty acids are absorbed and then metabolized via beta-oxidation similarly to dietary fatty acids. |
| Excretion | Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites. |
| Half-life | Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing. |
| Protein binding | Highly protein bound (>99%), primarily to albumin and to a lesser extent to alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution approximately 0.2 L/kg, indicating limited extravascular distribution. |
| Bioavailability | Intramuscular: ~100% (absolute bioavailability not determined in humans due to lack of IV formulation; presumed complete absorption from IM site). |
| Onset of Action | Intramuscular: Clinical effects on serum triglycerides observed within 2 weeks of first dose. |
| Duration of Action | Duration of triglyceride-lowering effect persists for approximately 2 weeks after last dose; sustained with weekly administration. |
4 g orally once daily as 4 capsules of 1 g each with food.
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for renal impairment, including end-stage renal disease on dialysis. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended for severe hepatic impairment (Child-Pugh C) due to lack of data. |
| Pediatric use | Safety and efficacy not established in pediatric patients under 18 years; no recommended dosing. |
| Geriatric use | No specific dose adjustment recommended; use with caution due to increased risk of adverse effects and comorbidities. Monitor hepatic function closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EPANOVA (EPANOVA).
| Breastfeeding | Excretion into human milk unknown. M/P ratio not available. Caution should be exercised when administered to a nursing mother. Because many drugs are excreted in human milk, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
| Teratogenic Risk | Pregnancy Category C. In animal reproduction studies, oral administration of icosapent ethyl to pregnant rats and rabbits during organogenesis at doses up to 5 and 7 times the human dose (based on body surface area) did not reveal evidence of harm to the fetus. However, there are no adequate and well-controlled studies in pregnant women. Fetal risk cannot be ruled out; use only if potential benefit justifies potential risk. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to Epanova or any of its components."]
| Precautions | ["May increase LDL-C levels; monitor LDL-C during therapy.","May prolong bleeding time; use with caution in patients receiving anticoagulants or with bleeding disorders.","Risk of atrial fibrillation or flutter in patients with prior cardiovascular disease or diabetes; discontinue if symptoms occur."] |
Loading safety data…
| Fetal Monitoring | Monitor serum triglycerides periodically during therapy. No specific fetal monitoring required beyond standard routine prenatal care. Monitor for signs of bleeding if anticoagulants are coadministered. |
| Fertility Effects | No studies on fertility effects in humans. In animal studies, oral administration of icosapent ethyl to male and female rats at doses up to 5 times the human dose (based on body surface area) had no effect on fertility or reproductive performance. |